Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:BCDA NASDAQ:CLRB NASDAQ:GLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.70-2.5%$1.59$1.26▼$4.50$12.36M2.29457,776 shs2,160 shsBCDABioCardia$1.13+3.2%$1.20$1.00▼$2.92$12.25M0.56113,209 shs4.40 million shsCLRBCellectar Biosciences$3.08-6.8%$2.92$2.43▼$20.60$12.91M0.43705,660 shs188,608 shsGLMDGalmed Pharmaceuticals$0.64+2.6%$0.62$0.41▼$2.34$3.52M0.622.16 million shs12,844 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos-3.33%-1.67%+12.57%-10.42%-36.51%BCDABioCardia-1.80%-4.39%-8.40%-12.80%-58.87%CLRBCellectar Biosciences-6.52%+26.92%+20.00%+8.55%-54.95%GLMDGalmed Pharmaceuticals-0.21%+9.91%+9.89%-5.63%-51.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.70-2.5%$1.59$1.26▼$4.50$12.36M2.29457,776 shs2,160 shsBCDABioCardia$1.13+3.2%$1.20$1.00▼$2.92$12.25M0.56113,209 shs4.40 million shsCLRBCellectar Biosciences$3.08-6.8%$2.92$2.43▼$20.60$12.91M0.43705,660 shs188,608 shsGLMDGalmed Pharmaceuticals$0.64+2.6%$0.62$0.41▼$2.34$3.52M0.622.16 million shs12,844 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos-3.33%-1.67%+12.57%-10.42%-36.51%BCDABioCardia-1.80%-4.39%-8.40%-12.80%-58.87%CLRBCellectar Biosciences-6.52%+26.92%+20.00%+8.55%-54.95%GLMDGalmed Pharmaceuticals-0.21%+9.91%+9.89%-5.63%-51.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 1.00SellN/AN/ABCDABioCardia 2.00Hold$25.002,122.22% UpsideCLRBCellectar Biosciences 2.33Hold$11.00257.72% UpsideGLMDGalmed Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest GLMD, AIMD, BCDA, and CLRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026CLRBCellectar Biosciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/21/2026GLMDGalmed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026BCDABioCardia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CLRBCellectar Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/10/2026CLRBCellectar Biosciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$124.16K99.55N/AN/A$1.29 per share1.32BCDABioCardia$60K205.13N/AN/A$0.08 per share14.06CLRBCellectar BiosciencesN/AN/AN/AN/A$1.89 per shareN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$2.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.77M-$3.53N/AN/AN/A-11,912.10%-140.10%-62.97%5/11/2026 (Estimated)BCDABioCardia-$8.23M-$1.29N/AN/AN/AN/A-28,372.40%-238.22%5/13/2026 (Estimated)CLRBCellectar Biosciences-$21.79M-$9.53N/AN/AN/AN/A-298.05%-144.59%5/12/2026 (Estimated)GLMDGalmed Pharmaceuticals-$10.31M-$1.24N/AN/AN/AN/A-29.43%-26.00%5/20/2026 (Estimated)Latest GLMD, AIMD, BCDA, and CLRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026BCDABioCardia-$0.17N/AN/AN/AN/AN/A5/12/2026Q1 2026CLRBCellectar Biosciences-$1.8850N/AN/AN/A$8.00 millionN/A3/30/2026Q4 2025AIMDAinosN/A-$0.85N/A-$0.85N/A$0.01 million3/24/2026Q4 2025BCDABioCardia-$0.20-$0.06+$0.14-$0.06$0.03 millionN/A3/4/2026Q4 2025CLRBCellectar Biosciences-$1.19-$0.53+$0.66-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos1.451.060.78BCDABioCardiaN/A1.121.12CLRBCellectar BiosciencesN/A2.962.96GLMDGalmed PharmaceuticalsN/A6.556.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/ABCDABioCardia20.57%CLRBCellectar Biosciences16.41%GLMDGalmed Pharmaceuticals76.14%Insider OwnershipCompanyInsider OwnershipAIMDAinos9.79%BCDABioCardia17.40%CLRBCellectar Biosciences5.04%GLMDGalmed Pharmaceuticals19.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos407.27 million6.56 millionNot OptionableBCDABioCardia4010.94 million9.04 millionOptionableCLRBCellectar Biosciences104.24 million4.03 millionNo DataGLMDGalmed Pharmaceuticals205.48 million4.39 millionNot OptionableGLMD, AIMD, BCDA, and CLRB HeadlinesRecent News About These CompaniesTissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based TherapeuticsMay 6 at 7:30 AM | prnewswire.comGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest UpdateApril 25, 2026 | defenseworld.netDGalmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain CancersApril 14, 2026 | prnewswire.comGLMD stock shot up 85% pre-market after rising 27% in 5 days – what’s the latest on its Parkinson’s disease therapy?April 9, 2026 | msn.comGalmed Stock Soars On Brain-Penetrating Aramchol FormulationApril 9, 2026 | benzinga.comGalmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, AramcholApril 9, 2026 | prnewswire.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025March 31, 2026 | prnewswire.comGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationJanuary 31, 2026 | finanznachrichten.deGalmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationJanuary 30, 2026 | prnewswire.comGalmed Pharmaceuticals’ Aramchol study: Key updates and market implicationsDecember 14, 2025 | msn.comGalmed Pharmaceuticals’ Aramchol abstract accepted for HEP-DART 2025 presentationDecember 9, 2025 | msn.comGalmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 MeetingDecember 8, 2025 | prnewswire.comGalmed stock rises after patent grant for MASH combo therapyDecember 4, 2025 | za.investing.comGalmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASHDecember 4, 2025 | prnewswire.comGalmed Pharmaceuticals stock rises on CEO’s optimistic outlookDecember 2, 2025 | za.investing.comGalmed Pharmaceuticals Shares Edge Higher Following CEO’s Positive UpdateDecember 2, 2025 | msn.comGalmed Issues CEO Letter to ShareholdersDecember 1, 2025 | prnewswire.comGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateNovember 26, 2025 | finanznachrichten.deGalmed Pharmaceuticals Reports Q3 2025 Financials and Research BreakthroughsNovember 26, 2025 | msn.comGalmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateNovember 26, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLMD, AIMD, BCDA, and CLRB Company DescriptionsAinos NASDAQ:AIMD$1.70 -0.04 (-2.52%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.BioCardia NASDAQ:BCDA$1.12 +0.04 (+3.21%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Cellectar Biosciences NASDAQ:CLRB$3.08 -0.23 (-6.82%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Galmed Pharmaceuticals NASDAQ:GLMD$0.64 +0.02 (+2.63%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
